ATTD 2021: Despite High Upfront Cost, Medtronic’s 780G Could Offer Cost Savings
In a talk at the 2021 Advanced Technologies & Treatments for Diabetes conference, Medtronic's European director of medical affairs explained how its MiniMed 780G insulin pump can reduce long-term treatment costs for diabetics.
You may also be interested in...
Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.
Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.
In a discussion with Medtech Insight, partners at Simon-Kucher & Partners explained that the pandemic has, and will continue to, transform both the sales and revenue models of medtech.